Flexion Therapeutics Inc. (NASDAQ:FLXN) insider Michael D. Clayman acquired 1,666 shares of the business’s stock in a transaction on Monday, November 21st. The stock was acquired at an average price of $17.90 per share, with a total value of $29,821.40. Following the transaction, the insider now directly owns 27,388 shares of the company’s stock, valued at approximately $490,245.20. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Flexion Therapeutics Inc. (NASDAQ:FLXN) traded up 2.6896% during mid-day trading on Wednesday, hitting $18.4944. The company had a trading volume of 260,823 shares. Flexion Therapeutics Inc. has a one year low of $7.56 and a one year high of $23.57. The company’s market cap is $509.10 million. The company’s 50 day moving average price is $19.37 and its 200-day moving average price is $16.56.

Flexion Therapeutics (NASDAQ:FLXN) last announced its earnings results on Monday, November 7th. The specialty pharmaceutical company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.63) by $0.02. Equities research analysts anticipate that Flexion Therapeutics Inc. will post ($2.76) EPS for the current fiscal year.

Insider Buying and Selling by Quarter for Flexion Therapeutics (NASDAQ:FLXN)

Several hedge funds have recently bought and sold shares of the company. American International Group Inc. increased its stake in Flexion Therapeutics by 8.2% in the second quarter. American International Group Inc. now owns 10,656 shares of the specialty pharmaceutical company’s stock worth $159,000 after buying an additional 810 shares in the last quarter. Metropolitan Life Insurance Co. NY purchased a new stake in Flexion Therapeutics during the second quarter worth approximately $176,000. Dynamic Technology Lab Private Ltd purchased a new stake in Flexion Therapeutics during the second quarter worth approximately $179,000. Bank of Montreal Can purchased a new stake in Flexion Therapeutics during the second quarter worth approximately $204,000. Finally, SECOR Capital Advisors LP purchased a new stake in Flexion Therapeutics during the third quarter worth approximately $214,000. 68.99% of the stock is currently owned by institutional investors.

Several research firms have issued reports on FLXN. BCS cut their price objective on Flexion Therapeutics from $0.65 to $0.02 in a research report on Tuesday, November 8th. Zacks Investment Research upgraded Flexion Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, November 2nd. Lake Street Capital reiterated a “buy” rating and issued a $38.00 price objective on shares of Flexion Therapeutics in a research report on Tuesday, September 6th. Finally, Cantor Fitzgerald reiterated a “buy” rating and issued a $40.00 price objective on shares of Flexion Therapeutics in a research report on Wednesday, November 2nd. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $28.28.

TRADEMARK VIOLATION NOTICE: “Flexion Therapeutics Inc. (FLXN) Insider Michael D. Clayman Purchases 1,666 Shares of Stock” was posted by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are reading this article on another domain, it was illegally stolen and reposted in violation of US and international copyright & trademark laws. The original version of this article can be viewed at https://www.thecerbatgem.com/2016/11/23/flexion-therapeutics-inc-flxn-insider-michael-d-clayman-purchases-1666-shares-of-stock.html.

About Flexion Therapeutics

Flexion Therapeutics, Inc is a specialty pharmaceutical company. The Company is focused on the development and commercialization of therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis and post-operative pain. The Company’s portfolio of product candidates addresses the OA pain treatment spectrum, from moderate to severe pain.

5 Day Chart for NASDAQ:FLXN

Receive News & Stock Ratings for Flexion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics Inc. and related stocks with our FREE daily email newsletter.